Eli Lilly

Novartis psoriasis drug tops J&J's Stelara in late-stage study

Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

Read Full Article

Novartis says three executives to leave after GSK, Lilly deals

Swiss drugmaker Novartis AG (NOVN.VX) said three members of its executive committee would leave the company following the completion of transactions with GlaxoSmithKline (GSK.L) and Eli Lilly (LLY.N) to divest three units.

Read Full Article

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal: sources

EU antitrust regulators will open an extensive probe into Zimmer's (ZMH.N) $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

Read Full Article

California big data startup BlueTalon bags $1.5M in seed funding for single-click data collaboration

California-based big data startup BlueTalon bagged $1.5 million in a seed funding round from Data Collective for its single-click data collaboration offering for enterprises.

Read Full Article

Lilly Chairman Returns to Work After Surgery

Eli Lilly Chairman, John Lechleiter has returned to work after heart surgery.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics